GE HealthCare (GEHC) competitors & alternatives
Health Care · NASDAQ
GE HealthCare (GEHC)'s top competitors and alternatives — its most similar public companies — include Agilent Technologies (A), BIODESIX INC (BDSX), FULGENT GENETICS INC (FLGT), Illumina, Inc. (ILMN), Thermo Fisher Scientific (TMO), Alnylam Pharmaceuticals (ALNY), KRYSTAL BIOTECH INC (KRYS), PTC THERAPEUTICS INC (PTCT), VERACYTE INC (VCYT), DYNE THERAPEUTICS INC (DYN), BEAM THERAPEUTICS INC (BEAM) and NURIX THERAPEUTICS INC (NRIX). These are GE HealthCare's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top GEHC competitors & alternatives
-
Agilent TechnologiesAHealth Care
A diversified healthcare and life sciences company providing analytical instruments, software, and services for pharmaceutical, chemical, and clinical…
$133.46 (as of 2026-07-22) · market cap $37.6B
-
BIODESIX INCBDSXHealth Care
Biodesix develops precision diagnostic tests powered by molecular and AI analysis to guide oncology treatment decisions for clinicians, payers, and…
$21.39 (as of 2026-07-22) · market cap $222M
-
FULGENT GENETICS INCFLGTHealth Care
Fulgent Genetics develops and offers a broad menu of genetic testing services for molecular diagnostics, helping clinicians interpret patient DNA for disease…
$19.53 (as of 2026-07-22) · market cap $555M
-
Illumina, Inc.ILMNHealth Care
Illumina is the global leader in DNA sequencing and array technologies that are foundational to modern genomics research and clinical diagnostics.
$190.87 (as of 2026-07-22) · market cap $29.2B
-
Thermo Fisher ScientificTMOHealth Care
Thermo Fisher Scientific is a leading global provider of mission-critical laboratory equipment, analytical instrumentation, and scientific services for…
$526.46 (as of 2026-07-22) · market cap $194.1B
-
Alnylam PharmaceuticalsALNYHealth Care
Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases.
$266.99 (as of 2026-07-22) · market cap $36.2B
-
KRYSTAL BIOTECH INCKRYSHealth Care
Krystal Biotech is a genetic medicine company leveraging its proprietary HSV-1 vector platform to treat rare diseases, headlined by its FDA-approved topical…
$336.80 (as of 2026-07-22) · market cap $9.9B
-
PTC THERAPEUTICS INCPTCTHealth Care
PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved…
$78.40 (as of 2026-07-22) · market cap $6.5B
-
VERACYTE INCVCYTHealth Care
Veracyte is a genomics-focused diagnostics company providing high-value clinical tests to improve cancer detection and treatment guidance for patients…
$58.01 (as of 2026-07-22) · market cap $4.8B
-
DYNE THERAPEUTICS INCDYNHealth Care
Dyne Therapeutics is a clinical-stage biotechnology company leveraging its proprietary FORCE platform to develop targeted therapies for serious,…
$23.21 (as of 2026-07-22) · market cap $3.8B
-
BEAM THERAPEUTICS INCBEAMHealth Care
Beam Therapeutics is developing base editing medicines—a precision genetic cure approach—for serious inherited diseases like sickle cell disease and rare…
$26.64 (as of 2026-07-22) · market cap $2.7B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
Not quite? Describe exactly what you want →
Peers are GE HealthCare's closest public companies by shared sub-industry, sector and business themes. See the full profile: GE HealthCare (GEHC).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.